Page last updated: 2024-11-07

r-1-(6-(r-2-carboxypyrrolidin-1-yl)-6-oxohexanoyl)pyrrolidine-2-carboxylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

miridesap: small molecule compound that depletes serum amyloid P component (SAP) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID125516
CHEMBL ID25263
SCHEMBL ID1537496
MeSH IDM0426169

Synonyms (54)

Synonym
cphpc
ro 63-8695
gsk2315698
CHEMBL25263
gsk-2315698
ro-638695
miridesap
ro-63-8695
(2r)-1-[6-[(2r)-2-carboxypyrrolidin-1-yl]-6-oxohexanoyl]pyrrolidine-2-carboxylic acid
(2r)-1-[6-[(2r)-2-carboxypyrrolidin-1-yl]-6-oxidanylidene-hexanoyl]pyrrolidine-2-carboxylic acid
ghe ,
r-1-(6-(r-2-carboxypyrrolidin-1-yl)-6-oxohexanoyl)pyrrolidine-2-carboxylic acid
unii-wo97n24a47
d-proline, 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-
(2r,2'r)-1,1'-(1,6-dioxo-1,6-hexanediyl)di(2-pyrrolidinecarboxylic acid)
miridesap [usan]
wo97n24a47 ,
224624-80-0
1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline
cpohpc acid
1,1'-(1,6-dioxo-1,6-hexanediyl)bis(d-proline
d-proline, 1,1'-(1,6-dioxo-1,6-hexanediyl)bis
(r)-1-(6-((r)-2-carboxy-pyrrolidin-1-yl)-6-oxo-hexanoyl)pyrrolidine-2-carboxylic acid
miridesap [inn]
1,1'-hexanedioyldi-d-proline
carboxy pyrrolidine hexanoyl pyrrolidine carboxylate
miridesap [who-dd]
gtpl8256
compound 52 [pmid 14998318]
HZLAWYIBLZNRFZ-VXGBXAGGSA-N
(r)-1-[6-[(r)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]-pyrrolidine-2-carboxylic acid
SCHEMBL1537496
DTXSID00176996
4AVT
AKOS030528069
cphpc(miridesap)
HY-101861
CS-0022098
DB13087
(2r,2'r)-1,1'-(1,6-dioxohexane-1,6-diyl)dipyrrolidine-2-carboxylic acid (non-preferred name)
BS-16672
r-1-[6-[r-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl] pyrrolidine-2-carboxylic acid
miridesap (usan/inn)
D11464
Q5013646
A17078
(2'r)-adipoyldi-d-proline
ro63-8695
D83697
(2r,2'r)-1,1'-adipoylbis(pyrrolidine-2-carboxylic acid)
A901596
AC-35760
ZIA62480
(2r,2'r)-1,1'-adipoylbis(pyrrolidine-2-carboxylicacid)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" No treatment-related adverse events were reported."( Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Intravenous Dose of Miridesap in Healthy Japanese Subjects.
Chen, C; Cookson, L; Doi, Y; Igarashi, H; Ino, H; Itoh, H; Liefaard, L; Nakano, A, 2019
)
0.51

Bioavailability

ExcerptReferenceRelevance
"Miridesap, a depleter of serum amyloid P component (SAP), forms an essential component of a novel approach to remove systemic amyloid deposits; low oral bioavailability necessitates that it is given parenterally."( Identification, preclinical profile, and clinical proof of concept of an orally bioavailable pro-drug of miridesap.
Bamford, M; Fernando, D; Haque, N; Holmes, DS; Kumar, S; Lewis, G; Liefaard, L; Richards, D; Storey, J; Thompson, D, 2020
)
0.56
" GSK294 showed good oral bioavailability of miridesap in rats and dogs."( Identification, preclinical profile, and clinical proof of concept of an orally bioavailable pro-drug of miridesap.
Bamford, M; Fernando, D; Haque, N; Holmes, DS; Kumar, S; Lewis, G; Liefaard, L; Richards, D; Storey, J; Thompson, D, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID200417Inhibitory concentration in serum amyloid component P (SAP)2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
Selective optimization of side activities: another way for drug discovery.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2014Acta crystallographica. Section D, Biological crystallography, Aug, Volume: 70, Issue:Pt 8
Interaction of serum amyloid P component with hexanoyl bis(D-proline) (CPHPC).
AID1346198Human amyloid P component, serum (Serum pentaxins)2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
Selective optimization of side activities: another way for drug discovery.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (41.18)29.6817
2010's7 (41.18)24.3611
2020's3 (17.65)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.48

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.48 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.48)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (23.53%)5.53%
Reviews5 (29.41%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (5.88%)0.25%
Other7 (41.18%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]